Intracellular dynamics and fate of a humanized anti-interleukin-6 receptor monoclonal antibody, Tocilizumab

Molecular Pharmacology

Volumn 88, Issue 4, 2015, Pages 660-675

  Fujimoto, Keiko ^a   Ida, Hiroaki ^a   Hirota, Yuko ^a   Ishigai, Masaki ^b   Amano, Jun ^b   Tanaka, Yoshitaka ^a  

^a KYUSHU UNIVERSITY   (Japan)

^b CHUGAI PHARMACEUTICAL CO LTD   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

CLATHRIN; FC RECEPTOR; GLYCOPROTEIN GP 130; INTERLEUKIN 6 RECEPTOR; TOCILIZUMAB; TRANSCRIPTION FACTOR AP 2; MONOCLONAL ANTIBODY;

ARTICLE; CELLULAR DISTRIBUTION; COMPLEX FORMATION; CONTROLLED STUDY; DRUG BINDING; ENDOCYTOSIS; ENDOSOME; HELA CELL LINE; HUMAN; HUMAN CELL; LYSOSOME; PRIORITY JOURNAL; PROTEIN DOMAIN; PROTEIN EXPRESSION; PROTEIN STABILITY; ANIMAL; ANTAGONISTS AND INHIBITORS; CHLOROCEBUS AETHIOPS; COS 1 CELL LINE; DRUG EFFECTS; INTRACELLULAR FLUID; METABOLISM;

ANIMALS; ANTIBODIES, MONOCLONAL, HUMANIZED; CERCOPITHECUS AETHIOPS; COS CELLS; HELA CELLS; HUMANS; INTRACELLULAR FLUID; RECEPTORS, INTERLEUKIN-6;

EID: 84946547405     PISSN: 0026895X     EISSN: 15210111     Source Type: Journal    
DOI: 10.1124/mol.115.099184     Document Type: Article

References (66)

1. Akilesh S, Christianson GJ, Roopenian DC, and Shaw AS (2007) Neonatal FcR expression in bone marrow-derived cells functions to protect serum IgG from catabolism. J Immunol 179:4580-4588.
2. Ataie-Kachoie P, Pourgholami MH, and Morris DL (2013) Inhibition of the IL-6 signaling pathway: A strategy to combat chronic inflammatory diseases and cancer. Cytokine Growth Factor Rev 24:163-173.
3. Bonifacino JS and Traub LM (2003) Signals for sorting of transmembrane proteins to endosomes and lysosomes. Annu Rev Biochem 72:395-447.
4. Chalaris A, Garbers C, Rabe B, Rose-John S, and Scheller J (2011) The soluble Interleukin 6 receptor: generation and role in inflammation and cancer. Eur J Cell Biol 90:484-494.
5. Di Guglielmo GM, Le Roy C, Goodfellow AF, and Wrana JL (2003) Distinct endocytic pathways regulate TGF-b receptor signalling and turnover. Nat Cell Biol 5: 410-421.
6. Dittrich E, Haft CR, Muys L, Heinrich PC, and Graeve L (1996) A di-leucine motif and an upstream serine in the interleukin-6 (IL-6) signal transducer gp130 mediate ligand-induced endocytosis and down-regulation of the IL-6 receptor. J Biol Chem 271:5487-5494.
7. Dittrich E, Rose-John S, Gerhartz C, Müllberg J, Stoyan T, Yasukawa K, Heinrich PC, and Graeve L (1994) Identification of a region within the cytoplasmic domain of the interleukin-6 (IL-6) signal transducer gp130 important for ligand-induced endocytosis of the IL-6 receptor. J Biol Chem 269:19014-19020.
8. Eskelinen EL, Tanaka Y, and Saftig P (2003) At the acidic edge: emerging functions for lysosomal membrane proteins. Trends Cell Biol 13:137-145.
9. Gan Z, Ram S, Vaccaro C, Ober RJ, and Ward ES (2009) Analyses of the recycling receptor, FcRn, in live cells reveal novel pathways for lysosomal delivery. Traffic 10:600-614.
10. Garbers C, Hermanns HM, Schaper F, Müller-Newen G, Grötzinger J, Rose-John S, and Scheller J (2012) Plasticity and cross-talk of interleukin 6-type cytokines. Cytokine Growth Factor Rev 23:85-97.
11. Garbers C, Jänner N, Chalaris A, Moss ML, Floss DM, Meyer D, Koch-Nolte F, Rose- John S, and Scheller J (2011) Species specificity of ADAM10 and ADAM17 proteins in interleukin-6 (IL-6) trans-signaling and novel role of ADAM10 in inducible IL-6 receptor shedding. J Biol Chem 286:14804-14811.
12. Gerhartz C, Dittrich E, Stoyan T, Rose-John S, Yasukawa K, Heinrich PC, and Graeve L (1994) Biosynthesis and half-life of the interleukin-6 receptor and its signal transducer gp130. Eur J Biochem 223:265-274.
13. Graeve L, Korolenko TA, Hemmann U, Weiergräber O, Dittrich E, and Heinrich PC (1996) A complex of the soluble interleukin-6 receptor and interleukin-6 is internalized via the signal transducer gp130. FEBS Lett 399:131-134.
14. Heuser JE and Anderson RG (1989) Hypertonic media inhibit receptor-mediated endocytosis by blocking clathrin-coated pit formation. J Cell Biol 108:389-400.
15. Hirota Y, Kuronita T, Fujita H, and Tanaka Y (2007) A role for Rab5 activity in the biogenesis of endosomal and lysosomal compartments. Biochem Biophys Res Commun 364:40-47.
16. Hirota Y and Tanaka Y (2009) A small GTPase, human Rab32, is required for the formation of autophagic vacuoles under basal conditions. Cell Mol Life Sci 66: 2913-2932.
17. Igawa T, Ishii S, Tachibana T, Maeda A, Higuchi Y, Shimaoka S, Moriyama C, Watanabe T, Takubo R, and Doi Y et al. (2010) Antibody recycling by engineered pH-dependent antigen binding improves the duration of antigen neutralization. Nat Biotechnol 28:1203-1207.
18. Ito H, Takazoe M, Fukuda Y, Hibi T, Kusugami K, Andoh A, Matsumoto T, Yamamura T, Azuma J, and Nishimoto N et al. (2004) A pilot randomized trial of a human antiinterleukin- 6 receptor monoclonal antibody in active Crohn's disease. Gastroenterology 126:989-996, discussion 947.
19. Johnson C, Han Y, Hughart N, McCarra J, Alpini G, and Meng F (2012) Interleukin-6 and its receptor, key players in hepatobiliary inflammation and cancer. Transl Gastrointest Cancer 1:58-70.
20. Jones EA and Waldmann TA (1972) The mechanism of intestinal uptake and transcellular transport of IgG in the neonatal rat. J Clin Invest 51:2916-2927.
21. Kelley SK, Gelzleichter T, Xie D, Lee WP, Darbonne WC, Qureshi F, Kissler K, Oflazoglu E, and Grewal IS (2006) Preclinical pharmacokinetics, pharmacodynamics, and activity of a humanized anti-CD40 antibody (SGN-40) in rodents and non-human primates. Br J Pharmacol 148:1116-1123.
22. Kuo TT and Aveson VG (2011) Neonatal Fc receptor and IgG-based therapeutics. MAbs 3:422-430.
23. Kuronita T, Eskelinen EL, Fujita H, Saftig P, Himeno M, and Tanaka Y (2002) A role for the lysosomal membrane protein LGP85 in the biogenesis and maintenance of endosomal and lysosomal morphology. J Cell Sci 115:4117-4131.
24. Kurosu H and Katada T (2001) Association of phosphatidylinositol 3-kinase composed of p110b-catalytic and p85-regulatory subunits with the small GTPase Rab5. J Biochem 130:73-78.
25. Lobo ED, Hansen RJ, and Balthasar JP (2004) Antibody pharmacokinetics and pharmacodynamics. J Pharm Sci 93:2645-2668.
26. Martens AS, Bode JG, Heinrich PC, and Graeve L (2000) The cytoplasmic domain of the interleukin-6 receptor gp80 mediates its basolateral sorting in polarized Madin-Darby canine kidney cells. J Cell Sci 113:3593-3602.
27. Masuyama N, Kuronita T, Tanaka R, Muto T, Hirota Y, Takigawa A, Fujita H, Aso Y, Amano J, and Tanaka Y (2009) HM1.24 is internalized from lipid rafts by clathrinmediated endocytosis through interaction with a-adaptin. J Biol Chem 284: 15927-15941.
28. Maxfield FR and McGraw TE (2004) Endocytic recycling. Nat Rev Mol Cell Biol 5: 121-132.
29. Montoyo HP, Vaccaro C, Hafner M, Ober RJ, Mueller W, and Ward ES (2009) Conditional deletion of the MHC class I-related receptor FcRn reveals the sites of IgG homeostasis in mice. Proc Natl Acad Sci USA 106:2788-2793.
30. Motley A, Bright NA, Seaman MN, and Robinson MS (2003) Clathrin-mediated endocytosis in AP-2-depleted cells. J Cell Biol 162:909-918.
31. Neurath MF and Finotto S (2011) IL-6 signaling in autoimmunity, chronic inflammation and inflammation-associated cancer. Cytokine Growth Factor Rev 22:83-89.
32. Ng CM, Stefanich E, Anand BS, Fielder PJ, and Vaickus L (2006) Pharmacokinetics/pharmacodynamics of nondepleting anti-CD4 monoclonal antibody (TRX1) in healthy human volunteers. Pharm Res 23:95-103.
33. Nishimoto N, Kanakura Y, Aozasa K, Johkoh T, Nakamura M, Nakano S, Nakano N, Ikeda Y, Sasaki T, and Nishioka K et al. (2005) Humanized anti-interleukin-6 receptor antibody treatment of multicentric Castleman disease. Blood 106:2627-2632.
34. Nishimoto N, Terao K, Mima T, Nakahara H, Takagi N, and Kakehi T (2008) Mechanisms and pathologic significances in increase in serum interleukin-6 (IL-6) and soluble IL-6 receptor after administration of an anti-IL-6 receptor antibody, tocilizumab, in patients with rheumatoid arthritis and Castleman disease. Blood 112:3959-3964.
35. Nishimoto N, Yoshizaki K, Maeda K, Kuritani T, Deguchi H, Sato B, Imai N, Suemura M, Kakehi T, and Takagi N et al. (2003) Toxicity, pharmacokinetics, and dose-finding study of repetitive treatment with the humanized anti-interleukin 6 receptor antibody MRA in rheumatoid arthritis. Phase I/II clinical study. J Rheumatol 30:1426-1435.
36. Nishimoto N, Yoshizaki K, Miyasaka N, Yamamoto K, Kawai S, Takeuchi T, Hashimoto J, Azuma J, and Kishimoto T (2004) Treatment of rheumatoid arthritis with humanized anti-interleukin-6 receptor antibody: A multicenter, double-blind, placebo-controlled trial. Arthritis Rheum 50:1761-1769.
37. Ober RJ, Martinez C, Lai X, Zhou J, and Ward ES (2004) Exocytosis of IgG as mediated by the receptor, FcRn: An analysis at the single-molecule level. Proc Natl Acad Sci USA 101:11076-11081.
38. Ohsugi Y and Kishimoto T (2008) The recombinant humanized anti-IL-6 receptor antibody tocilizumab, an innovative drug for the treatment of rheumatoid arthritis. Expert Opin Biol Ther 8:669-681.
39. Praetor A and Hunziker W (2002) b2-Microglobulin is important for cell surface expression and pH-dependent IgG binding of human FcRn. J Cell Sci 115: 2389-2397.
40. Raghavan M, Bonagura VR, Morrison SL, and Bjorkman PJ (1995) Analysis of the pH dependence of the neonatal Fc receptor/immunoglobulin G interaction using antibody and receptor variants. Biochemistry 34:14649-14657.
41. Raiborg C and Stenmark H (2009) The ESCRT machinery in endosomal sorting of ubiquitylated membrane proteins. Nature 458:445-452.
42. Rodewald R (1976) pH-dependent binding of immunoglobulins to intestinal cells of the neonatal rat. J Cell Biol 71:666-669.
43. Rodewald R and Kraehenbuhl JP (1984) Receptor-mediated transport of IgG. J Cell Biol 99:159s-164s.
44. Roopenian DC and Akilesh S (2007) FcRn: The neonatal Fc receptor comes of age. Nat Rev Immunol 7:715-725.
45. Rutledge EA, Mikoryak CA, and Draper RK (1991) Turnover of the transferrin receptor is not influenced by removing most of the extracellular domain. J Biol Chem 266:21125-21130.
46. Sato K, Tsuchiya M, Saldanha J, Koishihara Y, Ohsugi Y, Kishimoto T, and Bendig MM (1993) Reshaping a human antibody to inhibit the interleukin 6-dependent tumor cell growth. Cancer Res 53:851-856.
47. Scheller J, Chalaris A, Schmidt-Arras D, and Rose-John S (2011) The pro- And antiinflammatory properties of the cytokine interleukin-6. Biochim Biophys Acta 1813: 878-888.
48. Shields SB and Piper RC (2011) How ubiquitin functions with ESCRTs. Traffic 12: 1306-1317.
49. Simister NE, Jacobowitz Israel E, Ahouse JC, and Story CM (1997) New functions of the MHC class I-related Fc receptor, FcRn. Biochem Soc Trans 25:481-486.
50. Simister NE and Rees AR (1985) Isolation and characterization of an Fc receptor from neonatal rat small intestine. Eur J Immunol 15:733-738.
51. SpÎrchez M, Samaşca G, Iancu M, Bolba C, and Miu N (2012) Relation of interleukin- 6, TNF-alpha and interleukin-1alpha with disease activity and severity in juvenile idiopathic arthritis patients. Clin Lab 58:253-260.
52. Tabrizi M, Bornstein GG, and Suria H (2010) Biodistribution mechanisms of therapeutic monoclonal antibodies in health and disease. AAPS J 12:33-43.
53. Tabrizi MA, Tseng CM, and Roskos LK (2006) Elimination mechanisms of therapeutic monoclonal antibodies. Drug Discov Today 11:81-88.
54. Tanaka T, Narazaki M, and Kishimoto T (2011) Anti-interleukin-6 receptor antibody, tocilizumab, for the treatment of autoimmune diseases. FEBS Lett 585:3699-3709.
55. Tanaka T, Narazaki M, and Kishimoto T (2012) Therapeutic targeting of the interleukin-6 receptor. Annu Rev Pharmacol Toxicol 52:199-219.
56. Telleman P and Junghans RP (2000) The role of the Brambell receptor (FcRB) in liver: protection of endocytosed immunoglobulin G (IgG) from catabolism in hepatocytes rather than transport of IgG to bile. Immunology 100:245-251.
57. Tesar DB, Tiangco NE, and Bjorkman PJ (2006) Ligand valency affects transcytosis, recycling and intracellular trafficking mediated by the neonatal Fc receptor. Traffic 7:1127-1142.
58. Tzaban S, Massol RH, Yen E, Hamman W, Frank SR, Lapierre LA, Hansen SH, Goldenring JR, Blumberg RS, and Lencer WI (2009) The recycling and transcytotic pathways for IgG transport by FcRn are distinct and display an inherent polarity. J Cell Biol 185:673-684.
59. Ward ES, Zhou J, Ghetie V, and Ober RJ (2003) Evidence to support the cellular mechanism involved in serum IgG homeostasis in humans. Int Immunol 15: 187-195.
60. Ware MF, Tice DA, Parsons SJ, and Lauffenburger DA (1997) Overexpression of cellular Src in fibroblasts enhances endocytic internalization of epidermal growth factor receptor. J Biol Chem 272:30185-30190.
61. Weflen AW, Baier N, Tang QJ, Van den Hof M, Blumberg RS, Lencer WI, and Massol RH (2013) Multivalent immune complexes divert FcRn to lysosomes by exclusion from recycling sorting tubules. Mol Biol Cell 24:2398-2405.
62. Wernick NL, Haucke V, and Simister NE (2005) Recognition of the tryptophan-based endocytosis signal in the neonatal Fc Receptor by the m subunit of adaptor protein- 2. J Biol Chem 280:7309-7316.
63. Wu Z and Simister NE (2001) Tryptophan- And dileucine-based endocytosis signals in the neonatal Fc receptor. J Biol Chem 276:5240-5247.
64. Yokota S, Imagawa T, Mori M, Miyamae T, Aihara Y, Takei S, Iwata N, Umebayashi H, Murata T, and Miyoshi M et al. (2008) Efficacy and safety of tocilizumab in patients with systemic-onset juvenile idiopathic arthritis: A randomised, doubleblind, placebo-controlled, withdrawal phase III trial. Lancet 371:998-1006.
65. Zalevsky J, Chamberlain AK, Horton HM, Karki S, Leung IW, Sproule TJ, Lazar GA, Roopenian DC, and Desjarlais JR (2010) Enhanced antibody half-life improves in vivo activity. Nat Biotechnol 28:157-159.
66. Zohlnhöfer D, Graeve L, Rose-John S, Schooltink H, Dittrich E, and Heinrich PC (1992) The hepatic interleukin-6 receptor. Down-regulation of the interleukin-6 binding subunit (gp80) by its ligand. FEBS Lett 306:219-222.